V3 Brands Asia Pre-IPO - The Positives - Margins and Revenue Have Grown
V3 Brands Asia (V3 HK) is looking to raise about US$500m in its upcoming Hong Kong IPO. It was previously listed on the SGX between 2000-2016.
433 Views
RecBio (江苏瑞科) IPO Trading: Fairly Valued for Vaccine Hype
We provide an update for RecBio before trading debut. We think the company is fairly valued for the vaccine hype: COVID-19 vaccine for the short...
253 Views
RecBio (江苏瑞科) IPO: Fairly Valued on Optimistic Industry Forecast
We provide an update for the book building of the Jiangsu Recbio IPO. We think the deal is fairly valued on an optimistic industry forecast.
293 Views
RecBio (江苏瑞科) Pre-IPO: Thoughts on Valuation
Recbio is pre-marketing its USD 100-200m Hong Kong IPO. In this insight, we provide our thoughts on valuation for the company.
337 Views
RecBio (江苏瑞科) Pre-IPO: A Pure Proxy to HPV Vaccine Market
RecBio is an innovative vaccine player in China offering exposure to the high growth HPV vaccine market in China, though we are not convinced of...
267 Views